Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: A multicenter feasibility study (JCOG 0402)

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2253-2258

  Niho, S ^a   Ohe, Y ^a   Ishikura, S ^b   Atagi, S ^c   Yokoyama, A ^d   Ichinose, Y ^e   Okamoto, H ^f   Takeda, K ^g   Shibata, T ^h   Tamura, T ⁱ   Saijo, N ^j   Fukuoka, M ^j  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d Niigata Cancer Center   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^j KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Adenocarcinoma of the lung; Cisplatin; Gefitinib; Thoracic radiotherapy; Vinorelbine

Indexed keywords

CISPLATIN; GEFITINIB; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERTRANSAMINASEMIA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION PNEUMONIA; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

EID: 84863756498     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds012     Document Type: Article

References (28)

1. Albain KS, Crowley JJ, Turrisi AT, III et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-3460.
2. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
3. Yamamoto N, Nakagawa K, Nishimura Y et al. Phase III study comparing secondand third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28: 3739-3745.
4. Ohe Y, Ishizuka N, Tamura T et al. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci 2003; 94: 729-734.
5. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
6. Kudoh S, Kato H, Nishiwaki Y et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-1357.
7. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 2549-2556.
8. She Y, Lee F, Chen J et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003; 9: 3773-3778.
9. Tanaka T, Munshi A, Brooks C et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008; 14: 1266-1273.
10. Naito Y, Kubota K, Nihei K et al. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol 2008; 3: 617-622.
11. Pujol JL, Viens P, Rebattu P et al. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol 2006; 1: 417-424.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
15. Ready N, Janne PA, Bogart J et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGBstratified phase II trial. J Thorac Oncol 2010; 5: 1382-1390.
16. Wang J, Xia TY, Wang YJ et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81: e59-65.
17. Rothschild S, Bucher SE, Bernier J et al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III nonsmall cell lung cancer: a phase I trial. Int J Radiat Oncol Biol Phys 2011; 80: 126-132.
18. Okamoto I, Takahashi T, Okamoto H et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 2011; 72: 199-204.
19. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
20. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
21. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
22. Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 2010; 28: e273-274.
23. Ku GY, Chopra A, Lopes Gde L, Jr. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 2010; 70: 223-225.
24. Kijima T, Shimizu T, Nonen S et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol 2011; 29: e588-e590.
25. Segawa Y, Kiura K, Takigawa N et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2011; 28: 3299-3306.
26. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
27. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
28. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.